Research programme: Hsp60 cancer vaccine - DeveloGen

Drug Profile

Research programme: Hsp60 cancer vaccine - DeveloGen

Latest Information Update: 23 Sep 2010

Price : $50

At a glance

  • Originator DeveloGen
  • Class Cancer vaccines
  • Mechanism of Action Heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen
  • 17 Sep 2003 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top